YARS1 and breast cancer: Therefore, we assumed that therapeutic efficacy could be expected with combined treatment using a BCL2 inhibitor, such as ABT-263 (Navitoclax) and ABT-199 (Venetoclax), and an SM (LCL161) in YARS-positive breast cancer.